Analyst Price Targets — CARL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 1, 2026 9:56 am | David Saxon | Needham | $17.00 | $10.38 | TheFly | Carlsmed initiated with a Buy at Needham |
| April 15, 2026 12:25 pm | — | Truist Financial | $18.00 | $10.80 | TheFly | Carlsmed price target lowered to $18 from $20 at Truist |
| January 9, 2026 10:49 am | — | Goldman Sachs | $20.00 | $12.87 | TheFly | Carlsmed price target raised to $20 from $19 at Goldman Sachs |
| December 15, 2025 10:54 am | Ryan Zimmerman | BTIG | $24.00 | $12.95 | StreetInsider | BTIG Reiterates Buy Rating on Carlsmed Inc (CARL) |
| August 18, 2025 8:49 am | Matt O'Brien | Piper Sandler | $18.00 | $13.58 | TheFly | Carlsmed initiated with an Overweight at Piper Sandler |
Latest News for CARL
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.47 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CARL.
U.S. House Trading
No House trades found for CARL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.